Kaufman K*, Bernhardt K*, Symms K**.

*Motion Analysis Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.**Hanger Clinic,10910 Domain Drive,Suite 300,Austin, Tx 78758, USA

Functional assessment and satisfaction of transfemoral amputees with low mobility (FASTK2): A clinical trial of microprocessorcontrolled vs. non-microprocessor-controlled knees

Clinical Biomechanics 58 (2018) 116-122.

Products	C-Leg Compact, Rheo 3, Orion 2, Plié 3, NMPKs								
Major Findings	With C-Leg Compact, Rheo 3, Orion 2 and Plié 3 compared to NMPKs:								
	 Transfemoral amputees with limited mobility clearly benefit from MPKs: Activity Subjects spent significantly less time sitting (p = 0.01) and increased the amount of upright activity (p = 0.02). Complexity of the gait, as measured by the entropy**, increased by 25%, indicating a less pathological movement. Safety Significant reduction in falls (p = 0.01) 								
						→ Satisfactio - Significar - Greatest utility.	n: It improvement in P Improvements were	EQ satisfaction subscales seen in subscales ambul	s (p < 0.01). ation, appearance and
						Activity Level During Day			
	50 —								
	0 0 0 0 0 0 0 0 0 0 0 0 0 0								
		NMPK (Baseline/BL)	MPK (10 weeks after BL)	NMPK (14 weeks after BL)					

Activity in the free-living environment for the three time points of the study. When using the MPK, there was a significant increase in the amount of active time during the day (p = 0.02) (Kaufman et al, 2018).

Population	Subjects: Previous prosthesis: Amputation causes:	50 (28 males) unilateral transfemoral amputees Polycentric knee, friction brake, hydraulic, pneumatic Peripheral arterial disease (50%), Total knee arthroplasty infection (14%), infection (12%), trauma (10%), deep vein thrombosis (8%), cancer (4%) and	
	Mean age: Mean time since amputation: MFCL:	69 ± 9 years 1.5 years K2 (n=48) and K3 (n=2)	



Interventional, non-randomized, crossover study



Results

Activities Participation Environment Ramps, Hills Activity, Mobility, ADLs Preference, Satisfac-Safety ground, Obstacles tion, QoL Category Outcomes **NMPK** MPK **NMPK** Sig.* (Baseline) (after 10 weeks (after 4 weeks on on MPK) NMPK) Falls 0.0 Safety 2.0 3.0 --(IQR: 0.0 - 6.0) (IQR: 0.0-6.0) (IQR: 0.0-3.0) Activity, Mobility, **Time spent sitting** $64 \pm 3\%$ $61 \pm 5\%$ $52 \pm 3\%$ --Activities of Daily Time being active $16 \pm 2\%$ $20 \pm 2\%$ $18 \pm 2\%$ ++ Living (ADLs) Complexity of the gait 0.14 0.17 0.16 + (IQR: 0.07-0.32) (IQR: 0.07-0.45) (entropy**) (IQR: 0.05-0.27) Preference, PEQ There was a significant improvement in PEQ satisfaction sub-++Satisfaction, scales when using the MPK. The greatest improvements were Quality of Life in ambulation, appearance and utility. (QoL)

* no difference (0), positive trend (+), negative trend (-), significant (++/--), not applicable (n.a.)
** the sample entropy is used for assessing the complexity of physiological time-series signals. In this case, a more physiological gait is characterized by higher entropy i.e. a more complex, random gait pattern.

Author's Conclusion

"This clinical trial confirmed that the provision of a MPK to patients with a TFA and low, i.e. K2, mobility will result in improved function in the free-living environment, a reduction in falls and subsequently improved patient satisfaction." (Kaufman et al., 2018)

© 2018, Otto Bock HealthCare Products GmbH ("Otto Bock"), All Rights Reserved. This article contains copyrighted material. Wherever possible we give full recognition to the authors. We believe this constitutes a 'fair use' of any such copyrighted material according to Title 17 U.S.C. Section 107 of US Copyright Law. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner. All trademarks, copyrights, or other intellectual property used or referenced herein are the property of their respective owners. The information presented here is in summary form only and intended to provide broad knowledge of products offered. You should consult your physician before purchasing any product(s). Otto Bock disclaims any liability related from medical decisions made based on this article summary.

Ottobock | Functional assessment and satisfaction of transfemoral amputees with low mobility (FASTK2): A clinical trial of microprocessor-controlled vs. non-microprocessor-controlled knees C-Leg Compact, Rheo 3, Orion 2, Plié 3, NMPKs 3 of 3